Drugs developed to treat diabetes have recently doubled as a weight-loss tool for many patients. To help you understand what is going on in the pharmaceutical sector and what we expect to happen in the future, our highly-experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest...
Emerging fast onto the medical scene: A class of breakthrough weight-loss drugs. The vast potential has sparked excitement. But the looming challenges are vast, too.
About 70% of U.S. adults have weight issues — 42% are obese; another 30% are overweight. Excess fat raises the risk of type 2 diabetes, stroke, high blood pressure, heart disease and other issues. The financial cost is staggering: $260 billion in direct medical costs due to obesity in the U.S. in 2016, per one estimate. One-quarter of employers say obesity is the top factor for their health costs in a 2022 survey by the International Foundation of Employee Benefit Plans (IFEBP).
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Enter a new group of weight-loss drugs first used to treat diabetes. They mimic a gut hormone that decreases hunger and delays stomach emptying, so people eat less and don’t face severe cravings.
Denmark’s Novo Nordisk is today’s leader, with its diabetes drug Ozempic, approved in 2017, and Wegovy, OK’d in 2021, the first drug approved for weight loss since 2014. Eli Lilly’s Mounjaro was OK’d in 2022 for diabetes — approval for weight loss is likely this year. The drugs are injected weekly and led to a 15 -18% weight loss in trials. Both firms are working on oral pills. Pfizer, Amgen, OPKO Health, Germany’s Boehringer Ingelheim, China’s LeaderMed, Denmark’s Zealand Pharma and others are working on similar drugs, including pills.
Analysts forecast $50 billion to $100 billion in sales per year by 2030, versus $2.4 billion in 2022, with the U.S. initially seeing up to 90% of the market.
Prescriptions for weight management have soared for the approved drugs to more than 5 million in 2022, versus just 230,000 in 2019, according to Komodo Health, a health data platform. The costs of the drugs are extremely high: More than $1,000 per month for the injectables. In the coming years, competition and oral pills figure to reduce costs.
Employers and the federal government will soon face a cost conundrum. Today, 45% of companies with more than 5,000 employees cover prescription drugs for weight loss and 18% of companies with fewer than 5,000 employees do, according to the IFEBP. Many will use strict coverage rules as they brace for higher demand in coming years. Medicare doesn’t offer coverage yet, but if it did, costs could run to $27 billion per year if just 10% of obese adults aged 60 and over take the drugs, according to an article published in the New England Journal of Medicine. For Medicaid, only 10 states offer broad coverage for weight-loss drugs, per Bloomberg Businessweek.
Advocates are pushing hard for coverage, pointing to savings from improved health, though that could take years to pan out.
The drugs have been shown to be safe, but concerns remain. Side effects include a range of gastrointestinal problems: nausea, vomiting, diarrhea, gas, etc. One estimate is that side effects cause 10% or more of users to stop treatment. If users stop taking the drugs, they regain the weight.
Longer-term testing is needed both for safety and to show that reduced weight comes with other health benefits.
This forecast first appeared in The Kiplinger Letter, which has been running since 1923 and is a collection of concise weekly forecasts on business and economic trends, as well as what to expect from Washington, to help you understand what’s coming up to make the most of your investments and your money. Subscribe to The Kiplinger Letter.
Related Content
-
3 Ways to Stretch the 2026 Social Security COLA For Your BudgetThree steps retirees can take to stretch the Social Security COLA to fit their budgets.
-
How to Keep Your Charitable Giving Momentum Going All YearInstead of treating charity like a year-end rush for tax breaks, consider using smart tools like DAFs and recurring grants for maximum impact all the year.
-
Uber Takes Aim at the Bottom Lines of Billboard LawyersUber has filed lawsuits and proposed a ballot initiative, in California, to curb settlements it claims are falsely inflated by some personal injury lawyers.
-
An HSA Sounds Great for Taxes: Here’s Why It Might Not Be Right for YouHealth Savings Even with the promise of ‘triple tax benefits,’ a health savings account might not be the best health plan option for everyone.
-
Dental Cost Advice for New Retirees, From a New RetireeWhat I faced in my first dental bill after retiring.
-
Banks Are Sounding the Alarm About StablecoinsThe Kiplinger Letter The banking industry says stablecoins could have a negative impact on lending.
-
Big Changes Are Ahead for Higher EdThe Kiplinger Letter A major reform of higher ed is underway. Colleges are bracing for abrupt change, financial headwinds and uncertainty.
-
‘I Play Pickleball in Retirement.’ Is It HSA-Eligible?Retirement Tax Staying active after you retire may be easier with these HSA expenses. But there’s a big catch.
-
What New Tariffs Mean for Car ShoppersThe Kiplinger Letter Car deals are growing scarcer. Meanwhile, tax credits for EVs are on the way out, but tax breaks for car loans are coming.
-
What to Know About New Medicaid Cuts: Is Your Local Hospital Closing Soon?Tax Policy Trump’s ‘One Big Beautiful Bill’ is now law, and rural hospitals across the U.S. are on the chopping block.
-
AI’s Rapid Rise Sparks New Cyber ThreatsThe Kiplinger Letter Cybersecurity professionals are racing to ward off AI threats while also using AI tools to shore up defenses.
